4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-017057
Co-Chief Executive Officer sold 138,167 shares at an average $13.59 ($1,878,094)
- Co-Chief Executive Officer acquired 200,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-15 | Option exercise | +197,182 | $7.57 | $1,492,668 | 3,514,814 | D: show line 1 in the form |
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-15 | Sale | −136,193 | $13.59 | $1,850,795 | 3,378,621 | D: show line 2 in the form |
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-16 | Option exercise | +2,818 | $7.57 | $21,332 | 3,381,439 | D: show line 3 in the form |
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-16 | Sale | −1,974 | $13.83 | $27,299 | 3,379,465 | D: show line 4 in the form |
| Open-market sales · 138,167 sh · avg $13.59 · $1,878,094 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-15 | Option exercise · Stock Option (Right to Buy) | −197,182 | 2,818 | D: show line 5 in the form | ||
| Cohen Joshua B Co-Chief Executive Officer | 2026-01-16 | Option exercise · Stock Option (Right to Buy) | −2,818 | 0 | D: show line 6 in the form |
Loading xslF345X05/ownership.xml…